MedTrace Logo

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

NCT03218501 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2019-03-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405 for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of treatment.

Conditions

  • Uremic Pruritus in Hemodialysis Patients

Interventions

DRUG

SK-1405 high dose

SK-1405 high dose is to be administered orally once daily for 2 weeks

DRUG

SK-1405 low dose

SK-1405 low dose is to be administered orally once daily for 2 weeks

DRUG

Placebo

Placebo is to be administered orally once daily for 2 weeks

Sponsors & Collaborators

  • Sanwa Kagaku Kenkyusho Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2018-05-25
Completion
2018-05-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03218501 on ClinicalTrials.gov